Eupraxia Pharmaceuticals (EPRX) Competitors $5.28 -0.17 (-3.12%) Closing price 03:59 PM EasternExtended Trading$5.16 -0.12 (-2.27%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. NUVB, IMTX, SION, QURE, MNMD, AMLX, NAGE, STOK, VALN, and TNGXShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Nuvation Bio (NUVB), Immatics (IMTX), Sionna Therapeutics (SION), uniQure (QURE), Mind Medicine (MindMed) (MNMD), Amylyx Pharmaceuticals (AMLX), Niagen Bioscience (NAGE), Stoke Therapeutics (STOK), Valneva (VALN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Nuvation Bio Immatics Sionna Therapeutics uniQure Mind Medicine (MindMed) Amylyx Pharmaceuticals Niagen Bioscience Stoke Therapeutics Valneva Tango Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Does the media refer more to EPRX or NUVB? In the previous week, Nuvation Bio had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 9 mentions for Nuvation Bio and 5 mentions for Eupraxia Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.32 beat Eupraxia Pharmaceuticals' score of -0.21 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings and valuation, EPRX or NUVB? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Nuvation Bio. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.21Nuvation Bio$7.87M119.11-$567.94M-$0.63-4.37 Which has more volatility and risk, EPRX or NUVB? Eupraxia Pharmaceuticals has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Is EPRX or NUVB more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. Nuvation Bio's return on equity of -46.14% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -715.66% -128.13% Nuvation Bio -1,413.43%-46.14%-36.04% Do analysts prefer EPRX or NUVB? Eupraxia Pharmaceuticals presently has a consensus target price of $11.00, indicating a potential upside of 108.33%. Nuvation Bio has a consensus target price of $7.33, indicating a potential upside of 166.18%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders believe in EPRX or NUVB? 61.7% of Nuvation Bio shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryNuvation Bio beats Eupraxia Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.98M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-6.2120.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / BookN/A8.608.826.15Net Income-$25.50M-$54.65M$3.25B$265.06M7 Day Performance-1.51%5.43%4.05%2.80%1 Month Performance-5.55%6.75%4.32%1.68%1 Year Performance102.30%31.59%36.25%29.59% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals1.9757 of 5 stars$5.28-3.1%$11.00+108.3%+118.9%$195.98MN/A-6.2129News CoverageEarnings ReportGap UpNUVBNuvation Bio2.3588 of 5 stars$2.27-4.4%$7.17+216.4%-5.5%$770.69M$7.87M-0.9660Earnings ReportIMTXImmatics2.2746 of 5 stars$6.24-6.2%$14.67+135.2%-47.0%$757.99M$168.65M-36.68260News CoverageEarnings ReportSIONSionna Therapeutics2.1157 of 5 stars$17.15-2.2%$38.50+124.5%N/A$756.66MN/A0.0035Earnings ReportQUREuniQure2.7998 of 5 stars$13.48-3.7%$36.55+171.1%+107.4%$739.61M$14.34M-3.44500Positive NewsAnalyst UpgradeGap UpMNMDMind Medicine (MindMed)2.706 of 5 stars$9.66+0.2%$24.71+155.8%+51.3%$731.55MN/A-6.3340Gap UpAMLXAmylyx Pharmaceuticals3.3378 of 5 stars$8.17-0.1%$11.75+43.8%+317.1%$729.08M$87.37M-2.63200News CoverageEarnings ReportNAGENiagen Bioscience1.3699 of 5 stars$9.22+0.7%$13.22+43.4%N/A$726.26M$99.60M54.24120News CoverageAnalyst ForecastAnalyst RevisionSTOKStoke Therapeutics4.1246 of 5 stars$13.02+0.5%$25.80+98.2%+19.3%$711.98M$36.56M16.51100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownVALNValneva2.2996 of 5 stars$8.30+5.5%$15.50+86.7%+46.8%$706.25M$183.52M-6.97700Earnings ReportShort Interest ↑Gap DownTNGXTango Therapeutics2.0802 of 5 stars$6.40-7.5%$11.00+72.0%-24.0%$694.24M$42.07M-5.2590Positive NewsAnalyst RevisionGap Down Related Companies and Tools Related Companies Nuvation Bio Competitors Immatics Competitors Sionna Therapeutics Competitors uniQure Competitors Mind Medicine (MindMed) Competitors Amylyx Pharmaceuticals Competitors Niagen Bioscience Competitors Stoke Therapeutics Competitors Valneva Competitors Tango Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access